The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the first ...

The weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by the U.S. Food and Drug Administration (FDA) to treat obstructive sleep apnea ...

SAN DIEGO, Calif. (Ivanhoe Newswire) --- Obstructive sleep apnea, or OSA, affects nearly a billion people across the globe. It robs people of their sleep. They stop breathing sometimes 20 to 50 to 100 ...

Plaintiffs are going to court to challenge CVS Caremark’s decision to stop covering Zepbound, a weight-loss drug that is also used to treat sleep apnea. Plaintiff Martin Hamburger filed his lawsuit in ...

WASHINGTON — Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the blockbuster weight-loss treatment. The ...

INDIANAPOLIS (WISH) — Obstructive sleep apnea or OSA affects nearly a billion people across the globe. It robs people of their sleep — they stop breathing sometimes 20 to 50 to 100 times a night and ...

At World Sleep 2025, a discussion group examined the emerging role of GLP-1 receptor agonists in obstructive sleep apnea (OSA), particularly tirzepatide (Zepbound), which late last year became the ...

The FDA (Food and Drug Administration) has approved the first drug treatment for sleep apnea. permitting the use of a weight-loss medication for the condition that affects millions of Americans. On ...

The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea. The Food and Drug Administration on Friday authorized the use of Zepbound, made by ...